Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: MannKind Corporation

Capitalization 804M 693M 626M 601M 1.1B 73.9B 1.15B 7.4B 2.96B 35.44B 3.02B 2.95B 127B P/E ratio 2026 *
-418x
P/E ratio 2027 * 18.6x
Enterprise value 804M 693M 626M 601M 1.1B 73.9B 1.15B 7.4B 2.96B 35.44B 3.02B 2.95B 127B EV / Sales 2026 *
1.73x
EV / Sales 2027 * 1.52x
Free-Float
98.17%
Yield 2026 *
-
Yield 2027 * -
1 day-7.77%
1 week-20.43%
Current month-20.43%
1 month-54.84%
3 months-53.64%
6 months-53.14%
Current year-53.97%
1 week 2.58
Extreme 2.585
3.02
1 month 2.58
Extreme 2.585
6.05
Current year 2.58
Extreme 2.585
6.51
1 year 2.58
Extreme 2.585
6.51
3 years 2.58
Extreme 2.585
7.63
5 years 2.49
Extreme 2.49
7.63
10 years 0.67
Extreme 0.6662
11.2
Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 51 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Change 5d. change 1-year change 3-years change Capi.($)
-7.77%-20.43%-47.59%-45.40% 804M
-1.06%-5.20%+15.89%+90.71% 44.16B
+0.92%-4.81%+49.26%+16.70% 40.5B
-2.40%-6.16%+87.11%+614.58% 30.21B
-0.44%-7.92%-6.69%-21.24% 25.47B
-2.53%-8.57%+49.14%-33.42% 19.22B
-1.11%-8.08%+12.48%-31.71% 16.5B
-3.36%-0.96%+48.57%+161.21% 12.64B
+1.14%-8.92%-15.02%+894.08% 11.72B
-1.61%+1.28%+54.47% - 11.51B
Average -1.96%-6.77%+24.76%+182.83% 21.27B
Weighted average by Cap. -1.17%-5.41%+34.48%+169.04%

Financials

2026 *2027 *
Net sales 465M 401M 362M 347M 633M 42.7B 662M 4.28B 1.71B 20.48B 1.74B 1.71B 73.24B 528M 455M 411M 394M 719M 48.51B 752M 4.86B 1.95B 23.26B 1.98B 1.94B 83.19B
Net income 1.97M 1.7M 1.53M 1.47M 2.69M 181M 2.81M 18.14M 7.27M 86.91M 7.4M 7.24M 311M 60.28M 51.97M 46.92M 45.02M 82.09M 5.54B 85.91M 555M 222M 2.66B 226M 221M 9.5B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
06/03/26 2.610 $ -7.77% 9,457,117
05/03/26 2.830 $ -4.07% 6,384,217
04/03/26 2.950 $ +0.85% 7,061,400
03/03/26 2.925 $ -3.62% 5,146,731
02/03/26 3.035 $ -7.47% 10,456,411
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.610USD
Average target price
7.500USD
Spread / Average Target
+187.36%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW